Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 9:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pancreatic NET Clear all
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma
Interventions
Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
171
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced May 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Pancreatic Vipoma
Interventions
Bevacizumab, Everolimus, Octreotide Acetate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
388
States / cities
Mobile, Alabama • Anaheim, California • Antioch, California + 272 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced May 21, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Non Functioning Entero-pancreatic Endocrine Tumour
Interventions
lanreotide (Autogel formulation)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced May 21, 2026, 9:05 PM EDT
Withdrawn Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Pancreatic Neuroendocrine Tumor, Pancreas Cancer
Interventions
cytoreductive surgery, Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT), Peptide receptor radionuclide therapy (PRRT)
Procedure · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced May 21, 2026, 9:05 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Pancreatic Neuroendocrine Tumor
Interventions
Fulvestrant, 177Lu-DOTATATE
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced May 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
fosbretabulin tromethamine
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Stanford, California • Lexington, Kentucky • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced May 21, 2026, 9:05 PM EDT
No Longer Available No phase listed Expanded access
View directory record Official record
Conditions
Carcinoid Tumors, Islet Cell (Pancreatic NET), Other Neuroendocrine Tumors
Interventions
68Ga-DOTA TATE
Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced May 21, 2026, 9:05 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
433
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 290 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Digestive System Neuroendocrine Neoplasm, Duodenal Neuroendocrine Tumor G1, Functional Pancreatic Neuroendocrine Tumor, Gastric Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Nonfunctional Pancreatic Neuroendocrine Tumor, Thymus Neoplasm
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced May 21, 2026, 9:05 PM EDT
Terminated Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor
Interventions
bevacizumab, 5-fluorouracil, leucovorin, oxaliplatin
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
2
States / cities
San Francisco, California • Vallejo, California
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced May 21, 2026, 9:05 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Pancreatic Neuroendocrine Neoplasm
Interventions
Hereditary Cancer Panel
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced May 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Neuroendocrine Tumor, Islet Cell Tumor
Interventions
Sunitinib malate, Hepatic Artery Embolizations
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced May 21, 2026, 9:05 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced May 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
Interventions
PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Duarte, California • Denver, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced May 21, 2026, 9:05 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
Interventions
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
32
States / cities
Phoenix, Arizona • Duarte, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 21, 2026, 9:05 PM EDT
Active, not recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas
Interventions
[212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT
Drug · Diagnostic Test
Lead sponsor
David Bushnell
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced May 21, 2026, 9:05 PM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2
Interventions
Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography, Magnetic Resonance Imaging, Copper Cu 64 Dotatate, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced May 21, 2026, 9:05 PM EDT
Not listed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Neuroendocrine, Neuroendocrine Tumor, Neuroendocrine Cancer, Neuroendocrine Carcinoma, Carcinoid, Carcinoid Tumor, Islet Cell Tumor, Apudoma
Interventions
68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Kenner, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced May 21, 2026, 9:05 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions
MT-4561
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced May 21, 2026, 9:05 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm, Pancreatic Neuroendocrine Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Incomplete Freund''s Adjuvant, Magnetic Resonance Imaging, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
Procedure · Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced May 21, 2026, 9:05 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
Interventions
SOM230, RAD001
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced May 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
Interventions
AMG 706, octreotide
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
112
States / cities
Berwyn, Illinois • Chicago, Illinois • Joliet, Illinois + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced May 21, 2026, 9:05 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions
ENV-101 (taladegib)
Drug
Lead sponsor
Endeavor Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced May 21, 2026, 9:05 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Neuroendocrine Tumor (NET)
Interventions
Structured Lipid Medical Food
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 21, 2026, 9:05 PM EDT